+

US4977147A - 17-methylene- and 17-ethylidene-estratrienes - Google Patents

17-methylene- and 17-ethylidene-estratrienes Download PDF

Info

Publication number
US4977147A
US4977147A US07/280,803 US28080388A US4977147A US 4977147 A US4977147 A US 4977147A US 28080388 A US28080388 A US 28080388A US 4977147 A US4977147 A US 4977147A
Authority
US
United States
Prior art keywords
composition
administering
methyl
compound
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
US07/280,803
Inventor
Peter Jungblut
Rudolf Wiechert
Dieter Bittler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering AG filed Critical Schering AG
Assigned to SCHERING AKTIENGESELLSCHAFT, BERLIN AND BERGKAMEN reassignment SCHERING AKTIENGESELLSCHAFT, BERLIN AND BERGKAMEN ASSIGNMENT OF ASSIGNORS INTEREST. Assignors: JUNGBLUT, PETER, BITTLER, DIETER, WIECHERT, RUDOLF
Application granted granted Critical
Publication of US4977147A publication Critical patent/US4977147A/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Definitions

  • the invention relates to new pharmaceutical preparations and their use for treatment of menopausal complaints, estrogen deficiency and hormone-dependent tumors and for use as a contraceptive.
  • the pharmaceutical preparation is characterized by the content of one or more compounds of formula I ##STR2## wherein R 1 is hydrogen, methyl, a tetrahydropyranyl group or an acyl group and
  • R 2 is hydrogen or methyl.
  • Suitable acyl groups are physiologically compatible groups derived from acids customarily used for the esterification of hydroxy steroids. The identity and structure of the acyl moiety are not critical. Suitable acyl groups include organic carboxylic acids of 1-12 carbon atoms, e.g., hydrocarbon acids, pertaining to the aliphatic, cycloaliphatic, aromatic or aromatic-aliphatic series which can be saturated or unsaturated, mono- or poly-basic and/or substituted.
  • substituents examples include alkyl (e.g., of 1-4 C atoms), hydroxy, alkoxy (e.g., of 1-4 C atoms), oxo or amino groups (e.g., amino and mono- or dialkylamino (1-4 C-alkyl groups)) and halogen atoms.
  • alkyl e.g., of 1-4 C atoms
  • alkoxy e.g., of 1-4 C atoms
  • oxo or amino groups e.g., amino and mono- or dialkylamino (1-4 C-alkyl groups)
  • halogen atoms e.g., amino and mono- or dialkylamino (1-4 C-alkyl groups)
  • carboxylic acids of 1-12 carbon atoms include alkanoyl groups from formic acid, acetic acid, propionic acid, butyric acid, isobutyric acid, valeric acid, isovaleric acid, caproic acid, enanthic acid, caprylic acid, pelargonic acid, capric acid, undecylic acid, lauric acid, trimethylacetic acid, tertbutylacetic acid, cyclopentylacetic acid, diethylaminoacetic acid, lactic acid, succinic acid, adipic acid; other preferred groups include benzoic acid, nicotinic acid, morpholinoacetic acid, etc.
  • inorganic acids examples include sulfuric and phosphoric acids.
  • esters of succinic acid, adipic acid, sulfuric acid, and phosphoric acid can optionally be converted with an alkali into the water-soluble salts.
  • Hetero acyl groups can be derived from heterocyclic acids comprising 1-2 fused rings, wherein each ring contains 4-7 ring atoms and 1-2 hetero atoms, the hetero atoms comprising O, N and/or S.
  • Suitable acyl groups include that from pyrrolidino-, piperidino-, piperazino-, morpholinosulfonic acid, etc.
  • Suitable halogen atoms throughout the foregoing are fluorine, chlorine, bromine and iodine, preferably fluorine and chlorine.
  • 17-methylene-1,3,5(10)-estratrien-3-ol and the 3-acetate are described, for example, in J. Org. Chem. 1981, 46, 3326-3328, as intermediate products for production of D-homosteroids.
  • 17-ethylidene-1,3,5(10)-estratrien-3-ol is an intermediate product for production of the corresponding 17-beta ethyl compound (U.S. Pat. No. 3,946,052).
  • the patent also reports that these compounds have a significantly diminished estrogenic effect. The entire contents of this patent is hereby incorporated by reference.
  • estratrienes substituted in the 17-position by methylene or ethylidene are clearly different from estrones.
  • the compounds of formula I show a lower affinity to the estrogen receptors than estradiol, but as compared with estradiol, surprisingly bring about increased cellular membrane and blood/lymphatic vessel permeability.
  • the compounds of formula I show a lower affinity for the estrogen receptor.
  • the immature female rats receive estradiol or 17-methylene-1,3,5(10)-estratrien-3-ol subcutaneously once a day for 3 days. On the 4th day, the animals are sacrificed and the uterus weight or DNA content per uterus is determined.
  • a uterus weight of 50 mg or a DNA content of 302 micrograms is obtained with 0.07 microgram of estradiol or with 5 micrograms of 17-methylene-1,3,5(10)-estratrien-3-ol.
  • estradiol or 17-methylene-1,3,5(10)-estratrien-3-ol Upon local administration of estradiol or 17-methylene-1,3,5(10)-estratrien-3-ol into the uterine lumen of a female pig, a uterine edema is produced, the onset of which, using the 17-methylene compound, begins about 30 minutes later than with the estradiol but occurs to the same extent as with estradiol.
  • the extent of the edema can be determined by ascertaining the albumin and DNA content of the uterus.
  • Intrauterine injection of 1 ⁇ 10 -6 -molar solutions (20-50 ml/uterus) of the compounds to be tested was performed. With estradiol, an increase of the albumin content to about 17 mg of albumin/1 mg of DNA resulted after 120 minutes. With the corresponding 17-methylene compound, an increase to the same value resulted after 150 minutes.
  • test compound into a uterine horn of a female pig brings about edema formation only at that location; the untreated horn is not affected.
  • the finding for the compounds of formula I is an activity disproportionation indicating a lower activity in the cell nucleus (e.g., less transcription and/or translation) mediated by the estrogen receptor, with an edema formation that is unchanged as compared with estradiol.
  • the compounds of this invention are surprisingly useful estrogenic compounds despite their low affinity for the estrogen receptor, and contrary to the teachings of JP No. 71034421 for its compounds, due to this unexpected disproportionation of activity effects.
  • the compounds of formula I are substrates for intracellular enzymes, the products of which lead to an increase in cellular membrane and blood/lymphatic vessel permeability and thus edema, which can be demonstrated as so-called "water imbibition" in the form of a massive edema in the target organ, the uterus.
  • These compounds are especially suitable for the treatment of climacteric complaints, as well as generally for the treatment of symptoms occurring due to defunctionalization of the second activity segment of estradiol, e.g., osteoporosis, amenorrhea, troublesome side effects of monthly withdrawal bleeding, atrophic vaginitis, etc.
  • the active compounds are preferably administered orally, e.g. to mammals including humans, but they can also be administered locally and parenterally.
  • the active compounds are processed according to conventional methods for the customary forms of administration together with the additives, excipients and/or solubilizers customary in galenic pharmacy.
  • the preferred oral administration especially suitable are tablets, dragees, capsules, pills, aqueous suspensions or alcoholic solutions, and for local and parenteral administration, especially ointments and, respectively, oily solutions, such as, for example, sesame oil or castor oil solutions which can additionally contain, if desired, a solubilizer, e.g., benzyl benzoate.
  • the concentration of active compound in the pharmaceutical preparations depends on the type of administration and the field of usage.
  • tablets, dragees, capsules or pills can contain 50-200 ⁇ g of active compound per dosage unit, and oily solutions or ointments can contain 1-20 ⁇ g of active compound per milliliter.
  • the oral form of administration contains 50-150 ⁇ g of active agent.
  • This antitumor activity can be demonstrated using any conventional protocol, e.g., as described in Science 137 (1962), 257-262.
  • the compounds of formula I being substances with a selective estrogenic activity, can also be utilized in preparations for contraception, preferably in combination with a progestationally active hormone component, e.g., levonorgestrel, gestodene, or desogestrel.
  • a progestationally active hormone component e.g., levonorgestrel, gestodene, or desogestrel.
  • Forms of administration that can be given orally contain preferably 50-200 ⁇ g of a compound of formula I and 50-500 ⁇ g of a strongly effective gestagen per day.
  • the compounds are administered analogously to the known compound Microgynon®.
  • the compounds of formula I are either known or can be produced from known 3-hydroxy compounds according to methods known in the art by esterification or etherification.
  • esterification preferably takes place with pyridine/acid anhydride or pyridine/acid chloride at room temperature.
  • Alkylating compounds such as diazoalkanes or dialkylsulfates, can be used for the etherification.
  • Ten drops (0.5 ml) contain 50 ⁇ g of active compound.

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A pharmaceutical preparation for treating menopausal symptoms, estrogen deficiency and hormone-dependent tumors, and for use as a contraceptive, comprises a compound of formula I ##STR1## wherein R1 is hydrogen, methyl, a tetrahydropyranyl group or an acyl group and
R2 is hydrogen or methyl.

Description

SUMMARY OF THE INVENTION
The invention relates to new pharmaceutical preparations and their use for treatment of menopausal complaints, estrogen deficiency and hormone-dependent tumors and for use as a contraceptive.
The pharmaceutical preparation is characterized by the content of one or more compounds of formula I ##STR2## wherein R1 is hydrogen, methyl, a tetrahydropyranyl group or an acyl group and
R2 is hydrogen or methyl.
Suitable acyl groups are physiologically compatible groups derived from acids customarily used for the esterification of hydroxy steroids. The identity and structure of the acyl moiety are not critical. Suitable acyl groups include organic carboxylic acids of 1-12 carbon atoms, e.g., hydrocarbon acids, pertaining to the aliphatic, cycloaliphatic, aromatic or aromatic-aliphatic series which can be saturated or unsaturated, mono- or poly-basic and/or substituted. Examples that can be mentioned for the substituents are alkyl (e.g., of 1-4 C atoms), hydroxy, alkoxy (e.g., of 1-4 C atoms), oxo or amino groups (e.g., amino and mono- or dialkylamino (1-4 C-alkyl groups)) and halogen atoms. Among these are also the usual inorganic acids.
Examples of such carboxylic acids of 1-12 carbon atoms include alkanoyl groups from formic acid, acetic acid, propionic acid, butyric acid, isobutyric acid, valeric acid, isovaleric acid, caproic acid, enanthic acid, caprylic acid, pelargonic acid, capric acid, undecylic acid, lauric acid, trimethylacetic acid, tertbutylacetic acid, cyclopentylacetic acid, diethylaminoacetic acid, lactic acid, succinic acid, adipic acid; other preferred groups include benzoic acid, nicotinic acid, morpholinoacetic acid, etc.
Examples of inorganic acids include sulfuric and phosphoric acids.
The esters of succinic acid, adipic acid, sulfuric acid, and phosphoric acid can optionally be converted with an alkali into the water-soluble salts.
Hetero acyl groups can be derived from heterocyclic acids comprising 1-2 fused rings, wherein each ring contains 4-7 ring atoms and 1-2 hetero atoms, the hetero atoms comprising O, N and/or S. Suitable acyl groups include that from pyrrolidino-, piperidino-, piperazino-, morpholinosulfonic acid, etc.
Suitable halogen atoms throughout the foregoing are fluorine, chlorine, bromine and iodine, preferably fluorine and chlorine.
The compounds of formula I with R1 meaning hydrogen atom or acetyl are already known.
17-methylene-1,3,5(10)-estratrien-3-ol and the 3-acetate are described, for example, in J. Org. Chem. 1981, 46, 3326-3328, as intermediate products for production of D-homosteroids. 17-ethylidene-1,3,5(10)-estratrien-3-ol is an intermediate product for production of the corresponding 17-beta ethyl compound (U.S. Pat. No. 3,946,052). It is reported of 17-methylene compounds (and specifically 3-OH, 3-ethoxy, 3-benzoyloxy, 3-(2'-tetrahydropyranyloxy) and 3-methoxy 17-methylene estratriene) in Jap. Patent No. 71034421 (Chem. Abstracts Vol. 75 (1971) 151978z) that they are anticholesterol agents. The patent also reports that these compounds have a significantly diminished estrogenic effect. The entire contents of this patent is hereby incorporated by reference.
It has been found that the estratrienes substituted in the 17-position by methylene or ethylidene are clearly different from estrones. In comparison with the estrones, from which they are produced, the compounds of formula I show a lower affinity to the estrogen receptors than estradiol, but as compared with estradiol, surprisingly bring about increased cellular membrane and blood/lymphatic vessel permeability.
In the estrogen receptor binding test for estrogenic activity with the use of cytosol from pig uterus homogenate and of 6,73 H estradiol as the reference compound, the compounds of formula I show a lower affinity for the estrogen receptor.
The following table indicates the competition at the receptor in percent.
              TABLE                                                       
______________________________________                                    
Estrogen Receptor Binding Test                                            
Compound         Mol      % Competition                                   
______________________________________                                    
Estradiol        2 × 10.sup.-8                                      
                          49                                              
                 2 × 10.sup.-7                                      
                          88                                              
                 2 × 10.sup.-6                                      
                          96                                              
17-methylene-1,3,5(10)-                                                   
                 2 × 10.sup.-8                                      
                           8                                              
estratrien-3-ol  2 × 10.sup.-7                                      
                          25                                              
                 2 × 10.sup.-6                                      
                          73                                              
17-ethylidene-1,3,5(10)-                                                  
                 2 × 10.sup.-8                                      
                           5                                              
estratrien-3-ol  2 × 10.sup.-7                                      
                          11                                              
                 2 × 10.sup.-6                                      
                          48                                              
______________________________________
In the uterus growth test with immature, 23-day-old Sprague-Dawley rats, for example, 17-methylene-1,3,5(10)-estratrien-3-ol exhibits only 1/70 of the uterotropic activity of estradiol. The value of 1/70 of the estradiol is found both if it is based on the uterus wet weights including the intrauterine liquid, and if the DNA content is taken as measurement of the uterus cell content.
For performing the test, the immature female rats receive estradiol or 17-methylene-1,3,5(10)-estratrien-3-ol subcutaneously once a day for 3 days. On the 4th day, the animals are sacrificed and the uterus weight or DNA content per uterus is determined.
A uterus weight of 50 mg or a DNA content of 302 micrograms is obtained with 0.07 microgram of estradiol or with 5 micrograms of 17-methylene-1,3,5(10)-estratrien-3-ol.
Upon local administration of estradiol or 17-methylene-1,3,5(10)-estratrien-3-ol into the uterine lumen of a female pig, a uterine edema is produced, the onset of which, using the 17-methylene compound, begins about 30 minutes later than with the estradiol but occurs to the same extent as with estradiol. The extent of the edema can be determined by ascertaining the albumin and DNA content of the uterus.
Intrauterine injection of 1×10-6 -molar solutions (20-50 ml/uterus) of the compounds to be tested was performed. With estradiol, an increase of the albumin content to about 17 mg of albumin/1 mg of DNA resulted after 120 minutes. With the corresponding 17-methylene compound, an increase to the same value resulted after 150 minutes.
Introduction of the test compound into a uterine horn of a female pig brings about edema formation only at that location; the untreated horn is not affected.
Accordingly, the finding for the compounds of formula I is an activity disproportionation indicating a lower activity in the cell nucleus (e.g., less transcription and/or translation) mediated by the estrogen receptor, with an edema formation that is unchanged as compared with estradiol. Thus, the compounds of this invention are surprisingly useful estrogenic compounds despite their low affinity for the estrogen receptor, and contrary to the teachings of JP No. 71034421 for its compounds, due to this unexpected disproportionation of activity effects.
The compounds of formula I are substrates for intracellular enzymes, the products of which lead to an increase in cellular membrane and blood/lymphatic vessel permeability and thus edema, which can be demonstrated as so-called "water imbibition" in the form of a massive edema in the target organ, the uterus. These compounds are especially suitable for the treatment of climacteric complaints, as well as generally for the treatment of symptoms occurring due to defunctionalization of the second activity segment of estradiol, e.g., osteoporosis, amenorrhea, troublesome side effects of monthly withdrawal bleeding, atrophic vaginitis, etc.
The active compounds are preferably administered orally, e.g. to mammals including humans, but they can also be administered locally and parenterally. For this purpose, the active compounds are processed according to conventional methods for the customary forms of administration together with the additives, excipients and/or solubilizers customary in galenic pharmacy. For the preferred oral administration, especially suitable are tablets, dragees, capsules, pills, aqueous suspensions or alcoholic solutions, and for local and parenteral administration, especially ointments and, respectively, oily solutions, such as, for example, sesame oil or castor oil solutions which can additionally contain, if desired, a solubilizer, e.g., benzyl benzoate.
The concentration of active compound in the pharmaceutical preparations depends on the type of administration and the field of usage. Thus, for example, tablets, dragees, capsules or pills can contain 50-200 μg of active compound per dosage unit, and oily solutions or ointments can contain 1-20 μg of active compound per milliliter.
In a preferred embodiment, the oral form of administration contains 50-150 μg of active agent.
After treating therapeutically castrated women, as well as menopausal women, all of whom suffered from hot flashes and moodiness, with a daily dosage of 50-150 μg of active compound according to formula I, a marked decrease in discomfort occurred as early as after 2 days.
The systemic administration of compounds of formula I to Sprague-Dawley rats with mammary tumors induced by 7,12-dimethylbenzanthracene leads to cessation of tumor growth without any marked effect on the estrous cycle. The compounds are thus likewise suitable for the treatment of hormone-dependent tumors analogously to the known compound Tamoxifen. With the use of the compounds in amounts of 0.15-15 μg per kg, stimulation of growth of existing hormone-dependent tumors is prevented.
This antitumor activity can be demonstrated using any conventional protocol, e.g., as described in Science 137 (1962), 257-262.
The compounds of formula I, being substances with a selective estrogenic activity, can also be utilized in preparations for contraception, preferably in combination with a progestationally active hormone component, e.g., levonorgestrel, gestodene, or desogestrel. Forms of administration that can be given orally contain preferably 50-200 μg of a compound of formula I and 50-500 μg of a strongly effective gestagen per day. The compounds are administered analogously to the known compound Microgynon®.
The compounds of formula I are either known or can be produced from known 3-hydroxy compounds according to methods known in the art by esterification or etherification.
The esterification (acylation) preferably takes place with pyridine/acid anhydride or pyridine/acid chloride at room temperature.
Alkylating compounds, such as diazoalkanes or dialkylsulfates, can be used for the etherification.
Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The following preferred specific embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.
In the foregoing and in the following examples, all temperatures are set forth uncorrected in degrees Celsius and unless otherwise indicated, all parts and percentages are by weight.
The entire texts of all applications, patents and publications, if any, cited above and below, and of corresponding application, West German No. P 37 41 801.7, filed Dec. 7, 1987, are hereby incorporated by reference.
EXAMPLES Directions for Production of compounds of general Formula I (1) 17-Methylene-1,3,5(10)-estratrien-3-ol
74.6 ml of 15% butyllithium solution in hexane is instilled into a suspension of 44.0 g of methyltriphenylphosphonium bromide in 200 ml of dioxane under an argon stream and ice-bath cooling. It is then stirred for 1.5 hours more at room temperature. Then 6.0 g of 3-(tetrahydropyran-2'-yloxy)- 1,3,5(10)-estratrien-17-one is added, the hexane is distilled off up to boiling point of 100° C. and then the reaction mixture is refluxed for 19 hours. After ice water precipitation the substance is extracted with dichloromethane. After drying and concentration by evaporation the residue is chromatographed on silica gel, and 6.1 g of 17-methylene-3-(tetrahydropyran-2'-yloxy)-1,3,5(10)-estratriene with a melting point of 73.5 ° C. is obtained.
6 ml of 8% by volume of sulfuric acid is added to a solution of 6.0 g of 17-methylene-3-(tetrahydropyran-2'-yloxy)-1,3,5(10)-estratriene in 60 ml of methanol and is allowed to stand for 4 hours at room temperature. Then reaction solution is then diluted with ether, washed with water, dried and concentrated by evaporation. The residue is recrystallized from hexane and 4.1 g of 17-methylene-1,3,5(10)-estratrien-3-ol with a melting point of 133.5° C. is obtained.
(2) 3-Methoxy-17-methylene-1,3,5(10)-estratriene
200 mg of 17-methylene-1,3,5(10)-estratrien-3-ol is dissolved in 115 ml of 0.5 molar sodium hydroxide solution, is mixed with 2.5 ml of dimethyl sulfate and stirred overnight at room temperature. The reaction solution is extracted with dichloromethane, the organic phase is washed with water, dried and concentrated by evaporation. The residue is chromatographed on silica gel, and 170 mg of 3-methoxy-17-methylene-1,3,5(10)-estratriene is obtained.
(3) 3-Acetoxy-17-methylene-1,3,5(10)-estratriene
200 mg of 17-methylene-1,3,5(10)-estratrien-3-ol in 1 ml of pyridine and 0.5 ml of acetic anhydride is allowed to stand overnight at room temperature. It is then diluted with ice water, the precipitated precipitate is filtered off, taken up in dichloromethane, dried and concentrated by evaporation. The residue is chromatographed on silica gel, and 185 mg of 3-acetoxy 17-methylene-1,3,5(10)-estratriene is obtained.
(4) 3-Butyryloxy-17-methylene-1,3,5(10)-estratriene
250 mg of 17-methylene-1,3,5(10)-estratrien-3-ol is reacted in 1.5 ml of pyridine with 0.75 ml of butyric acid anhydride and worked up as described in example 3. After chromatography on silica gel, 245 mg of 3-butyryloxy-17-methylene-1,3,5(10)-estratriene is obtained.
(5) 17-Ethylidene-1,3,5(10)-estratrien-3-ol
3.22 g of potassium tert-butylate in added by portions to a suspension of 10.6 g of ethyltriphenylphoshonium bromide in 50 ml of dimethyl sulfoxide and stirred for 1 more hour at room temperature. Then a solution of 4.0 g of tert-butyl-dimethylsilyloxy-1,3,5(10)-estratrien-17-one in 50 ml of dimethyl sulfoxide is instilled and stirred for 3 more hours at room temperature. The reaction solution is diluted with ether, washed with water, dried and concentrated by evaporation. The residue is chromatographed on silica gel, and 450 mg of (syn) 17-ethylidene-1,3,5(10)-estratrien-3-ol is obtained.
(6) 17-Ethylidene-1,3,5(10)-estratriene-3-methyl ether
100 mg of (syn) 17-ethylidene-1,3,5(10)-estratrien-3-one in 57.5 ml of 0.5 molar sodium hydroxide solution is reacted with 1.25 ml of dimethyl sulfate and worked up as described in example 2. After chromatography on silica gel, 75 mg of (syn) 17-ethylidene-1,3,5(10)-estratriene-3-methyl ether is obtained.
(7) 17-Ethylidene-3-propionyloxy-1,3,5(10)-estratriene
100 mg of (syn) 17-ethylidene-1,3,5(10)-estratrien-3-ol in 1 ml of pyridine is reacted with 0.5 ml of propionic acid anhydride and worked up as described in example 3. After chromatography on silica gel, 95 mg of (syn) 17-ethylidene-=3-propionyloxy-1,3,5(10)-estratriene is obtained.
EXAMPLE 1 Composition of a dragee 
______________________________________                                    
Example 1                                                                 
Composition of a dragee                                                   
______________________________________                                    
 0.050 mg                                                                 
         l7-methylene-l,3,5(10)-estratrien-3-ol                           
46.450 mg                                                                 
         Lactose                                                          
26.800 mg                                                                 
         Corn starch                                                      
 3.000 mg                                                                 
         Poly(1-vinyl-2-pyrrolidone) average MW 25,000                    
 3.700 mg                                                                 
         Talc                                                             
80.000 mg                                                                 
         Total weight, supplemented to about 140 mg                       
         with the usual sugar mixture                                     
______________________________________
EXAMPLE 2 Composition of an alcoholic solution
1 mg of 17-methylene-1,3,5(10)-estratrien-3-ol is dissolved in 10 ml of 46% ethyl alcohol.
Ten drops (0.5 ml) contain 50 μg of active compound.
The preceding examples can be repeated with similar success by substituting the generically or specifically described reactants and/or operating conditions of this invention for those used in the preceding examples.
From the foregoing description, one skilled in the art can easily ascertain the essential characteristics of this invention and, without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions.

Claims (23)

What is claimed is:
1. A composition comprising a compound of formula I ##STR3## wherein R1 is methyl, tetrahydropyranyl or the acyl group of a C1-12 hydrocarbon carboxylic acid or a heterocyclic acid having 1-2 fused rings, wherein each ring contains 4-7 ring atoms and 1-2 hetero contains 4-7 ring aotms and 1-2 hetero atoms which are O, N and/or S, said acyl groups being optionally substituted by C1 -4 alkyl, hydroxy, C4-4 -alkoxy, oxo, amino or halogen, or of a mineral acid, and
R2 is methyl,
and a pharmaceutically acceptable excipient.
2. A composition comprising a compound of formula I ##STR4## wherein R1 is the acyl group of a C1-12 hydrocarbon carboxylic acid or a heterocyclic acid having 1-2 fused rings, wherein each ring contains 4-7 ring atoms and 1-2 hetero atoms which are O, N and/or S, said acyl groups being optionally substituted by C1-4 alkyl, hydroxy, C4- -alkoxy, oxo, amino or halogen, or of a mineral acid, and
R2 is hydrogen,
and a pharmaceutically acceptable excipient.
3. A composition of claim 1, wherein R1 is alkanoyl.
4. A composition of claim `, wherein R1 is alkanoyl.
5. A composition of claim 1, wherein the amount of said compound is 50-200 μg.
6. A composition of claim 2, wherein the amount of said compound is 50-200 μg.
7. A method of treating menopausal symptoms, comprising administering a composition comprising a compound of formula I ##STR5## wherein R1 is hydrogen, methyl, tetrahydropyranyl or the acyl group of a C1-12 hydrocarbon carboxylic acid or a heterocyclic acid having 1-2 fused rings, wherein each ring contains 4-7 ring atoms and 1-2 hetero atoms which are O, N and/or S, said acyl groups being optionally substituted by C1-4 alkyl, hydroxy, C1-4 -alkoxy, oxo, amino or halogen, or of a mineral acid, and
R2 is hydrogen or methyl,
and a pharmaceutically acceptable excipient.
8. A method of treating estrogen deficiency, comprising administering a composition comprising a compound of formula I ##STR6## wherein R1 is hydrogen, methyl, tetrahydropyranyl or the acyl group of a C1-12 hydrocarbon carboxylic acid or a heterocyclic acid having 1-2 fused rings, wherein each ring contains 4-7 ring atoms and 1-2 hetero atoms which are 0, N and/or S, said acyl groups being optionally substituted by C1-4 alkyl, hydroxy, C1-4 -alkoxy, oxo, amino or halogen, or of a mineral acid, and
R2 is hydrogen or methyl,
and a pharmaceutically acceptable excipient.
9. A method of treating hormone-dependent tumors, comprising administering a composition comprising a compound of formula I ##STR7## wherein R1 is hydrogen, methyl, tetrahydropyranyl or the acyl group of a C1-12 hydrocarbon carboxylic acid or a heterocyclic acid having 1-2 fused rings, wherein each ring contains 4-7 ring atoms and 1-2 hetero atoms which are O, N and/or S, said acyl groups being optionally substituted by C1-4 alkyl, hydroxy, C1-4 -alkoxy, oxo, amino or halogen, or of a mineral acid, and
R2 is hydrogen or methyl,
and a pharmaceutically acceptable excipient.
10. A method of preventing pregnancy, comprising administering to a female mammal a composition a compound of formula I ##STR8## wherein R1 is hydrogen, methyl, tetrahydropyranyl or the acyl group of a C1-12 hydrocarbon carboxylic acid or a heterocyclic acid having 1-2 fused rings, wherein each ring contains 4-7 ring atoms and 1-2 hetero atoms which are O, N and/or S, said acyl groups being optionally substituted by C1-4 alkyl, hydroxy, C1-4 -alkoxy, oxo, amino or halogen, or of a mineral acid, and
R2 is hydrogen or methyl,
and a pharmaceutically acceptable excipient.
11. A method of preventing pregnancy, comprising administering to a female mammal, in combination, a composition, comprising a compound of formula I ##STR9## wherein R1 is hydrogen, methyl, tetrahydropyranyl or the acyl group of a C1-12 hydrocarbon carboxylic acid or a heterocyclic acid having 1-2 fused rings, wherein each ring contains 4-7 ring atoms and 1-2 hetero atoms which are O, N and/or S, said acyl groups being optionally substituted by C1-4 alkyl, hydroxy, C1-4 -alkoxy, oxo, amino or halogen, or of a mineral acid, and
R2 is hydrogen or methyl,
a progestationally active compound and a pharmaceutically acceptable excipient.
12. A method of treating menopausal symptoms comprising administering a composition of claim 1.
13. A method of treating menopausal symptoms, comprising administering a composition of claim 2.
14. A method of treating estrogen deficiency, comprising administering a composition of claim 1.
15. A method of treating estrogen.. deficiency, comprising administering a composition of claim 2.
16. A method of treating hormone-dependent tumors, comprising administering a composition of claim 1.
17. A method of treating hormone-dependent tumors, comprising administering a composition of claim 2.
18. A method of preventing pregnancy, comprising administering to a female mammal a composition of claim 1.
19. A method of preventing pregnancy, comprising administering to a female mammal a composition of claim 2.
20. A method of preventing pregnancy, comprising administering to a female mammal, in combination, a composition of claim 1 and a progestationally active compound.
21. A method of preventing pregnancy, comprising administering to a female mammal, in combination, a composition of claim 2 and a progestationally active compound
22. A composition of claim 1, wherein the compound is 17-ethylidene-1,3,5(10)-estratriene methyl ether or 17-ethylidene-3-propionyloxy-1,3,5(10)-estratriene.
23. A composition of claim 2, wherein the compound is 3-acetoxy-17-methylene-1,3,5(10)-estratriene or 3-butyryloxy-17-methylene-1,3,5(10)-estratriene.
US07/280,803 1987-12-07 1988-12-07 17-methylene- and 17-ethylidene-estratrienes Expired - Fee Related US4977147A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19873741801 DE3741801A1 (en) 1987-12-07 1987-12-07 17-Methylene-estratrienes
DE3741801 1987-12-07

Publications (1)

Publication Number Publication Date
US4977147A true US4977147A (en) 1990-12-11

Family

ID=6342258

Family Applications (1)

Application Number Title Priority Date Filing Date
US07/280,803 Expired - Fee Related US4977147A (en) 1987-12-07 1988-12-07 17-methylene- and 17-ethylidene-estratrienes

Country Status (6)

Country Link
US (1) US4977147A (en)
EP (1) EP0320437A3 (en)
JP (1) JPH01197438A (en)
AU (1) AU621844B2 (en)
CA (1) CA1329770C (en)
DE (1) DE3741801A1 (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0715517A1 (en) * 1993-06-15 1996-06-12 Pherin Corporation Estrene steroids as neurochemical initiators of change in human hypothalamic function and related pharmaceutical compositions and methods
WO1997008188A1 (en) * 1995-08-23 1997-03-06 Astra Aktiebolag Novel estrogens
US5861431A (en) * 1995-06-07 1999-01-19 Iotek, Inc. Incontinence treatment
US6660726B2 (en) 2000-03-10 2003-12-09 Endeavor Pharmaceuticals Estrogenic compounds, pharmaceutical compositions thereof, and methods of using same
US20040198670A1 (en) * 2003-04-04 2004-10-07 Hill Edward N. Novel estrogenic compounds
US20040259851A1 (en) * 2003-04-11 2004-12-23 Leonard Thomas W. Methods of administering estrogens and progestins
US6855703B1 (en) 2000-03-10 2005-02-15 Endeavor Pharmaceuticals Pharmaceutical compositions of conjugated estrogens and methods of analyzing mixtures containing estrogenic compounds
WO2006002907A1 (en) * 2004-06-29 2006-01-12 Jadolabs Gmbh Use of steroid-derived pharmaceutical compositions for treating disorders relating to pathological processes in lipid rafts
US20070142307A1 (en) * 2000-03-10 2007-06-21 Barr Laboratories, Inc. Novel estrogenic compounds
US20100234330A1 (en) * 2003-07-23 2010-09-16 Hill Edward N Novel Estrogenic Compounds

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU705422B2 (en) * 1994-09-29 1999-05-20 Pherin Pharmaceuticals, Inc. Novel estrenes for inducing hypothalamic effects

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3946052A (en) * 1975-06-16 1976-03-23 Stanford Research Institute 19-Norpregna- 1,3,5(10)-trien-3-ol and loweralkyl homologs thereof having postcoital antifertility activity

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2332759A1 (en) * 1975-11-26 1977-06-24 Roussel Uclaf (17)-Hydroxymethyl gona-(1,3,5)-triene derivs. - with antioestrogen and hypophysis inhibiting activities

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3946052A (en) * 1975-06-16 1976-03-23 Stanford Research Institute 19-Norpregna- 1,3,5(10)-trien-3-ol and loweralkyl homologs thereof having postcoital antifertility activity

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
J. Org. Chem 46, 3326 3328 (1981). *
J. Org. Chem 46, 3326-3328 (1981).

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0715517A1 (en) * 1993-06-15 1996-06-12 Pherin Corporation Estrene steroids as neurochemical initiators of change in human hypothalamic function and related pharmaceutical compositions and methods
EP0715517A4 (en) * 1993-06-15 2000-10-11 Pherin Corp ESTRENE STEROIDS FOR USE AS NEUROCHEMICAL INITIATORS OF MODIFYING HUMAN HYPOTHALAMIC FUNCTION AND PHARMACEUTICAL COMPOSITIONS AND METHODS
US5861431A (en) * 1995-06-07 1999-01-19 Iotek, Inc. Incontinence treatment
WO1997008188A1 (en) * 1995-08-23 1997-03-06 Astra Aktiebolag Novel estrogens
US6043236A (en) * 1995-08-23 2000-03-28 Astra Aktiebolag Estrogens
US7459445B2 (en) 2000-03-10 2008-12-02 Duramed Pharmaceuticals, Inc. Estrogenic compounds and topical pharmaceutical formulations of the same
US7179799B2 (en) 2000-03-10 2007-02-20 Barr Laboratories, Inc. (3) and (6) substituted estrogenic compounds
US8227454B2 (en) 2000-03-10 2012-07-24 Duramed Pharmaceuticals, Inc. Estrogenic compounds, pharmaceutical compositions and formulations comprising the same
US6844334B2 (en) 2000-03-10 2005-01-18 Endeavor Pharmaceuticals (3) and (6) substitued estrogenic compounds
US6855703B1 (en) 2000-03-10 2005-02-15 Endeavor Pharmaceuticals Pharmaceutical compositions of conjugated estrogens and methods of analyzing mixtures containing estrogenic compounds
US7749989B2 (en) 2000-03-10 2010-07-06 Duramed Pharmaceuticals, Inc. Estrogenic compounds, methods of using and methods of administering the same
US20090105198A1 (en) * 2000-03-10 2009-04-23 Duramed Pharmaceuticals, Inc. Novel estrogenic compounds
US6660726B2 (en) 2000-03-10 2003-12-09 Endeavor Pharmaceuticals Estrogenic compounds, pharmaceutical compositions thereof, and methods of using same
US20070142307A1 (en) * 2000-03-10 2007-06-21 Barr Laboratories, Inc. Novel estrogenic compounds
US20040198670A1 (en) * 2003-04-04 2004-10-07 Hill Edward N. Novel estrogenic compounds
US6992075B2 (en) 2003-04-04 2006-01-31 Barr Laboratories, Inc. C(14) estrogenic compounds
US20040259851A1 (en) * 2003-04-11 2004-12-23 Leonard Thomas W. Methods of administering estrogens and progestins
US20100234330A1 (en) * 2003-07-23 2010-09-16 Hill Edward N Novel Estrogenic Compounds
US7989436B2 (en) 2003-07-23 2011-08-02 Duramed Pharmaceuticals, Inc. Estrogenic compounds and pharmaceutical formulations comprising the same
US20080255076A1 (en) * 2004-06-29 2008-10-16 Jadolabs Gmbh Steroid-Derived Pharmaceutical Compositions
WO2006002907A1 (en) * 2004-06-29 2006-01-12 Jadolabs Gmbh Use of steroid-derived pharmaceutical compositions for treating disorders relating to pathological processes in lipid rafts

Also Published As

Publication number Publication date
JPH01197438A (en) 1989-08-09
EP0320437A3 (en) 1991-07-31
CA1329770C (en) 1994-05-24
DE3741801A1 (en) 1989-06-15
EP0320437A2 (en) 1989-06-14
AU2665388A (en) 1989-06-08
AU621844B2 (en) 1992-03-26

Similar Documents

Publication Publication Date Title
JP4368945B2 (en) Novel 19-noroop legnene derivatives
EP2039701B1 (en) 20-Keto-11Beta-Arylsteroids and their Derivatives having agonist or antagonist hormonal activity
US5089488A (en) β-(4-isopropenylphenyl)estra-4,9-dienes, their production, and pharmaceutical preparations containing same
WO1997027209A1 (en) New substituted 19-nor-pregnane derivatives
US4977147A (en) 17-methylene- and 17-ethylidene-estratrienes
JP5043681B2 (en) 18-methyl-19-nor-17-pregn-4-ene-21,17-carbolactone and formulations containing the same
EP1135403B1 (en) 17beta-acyl-17alpha-propynyl-11beta-arylsteroids and their derivatives having agonist or antagonist hormonal properties
JP3026997B2 (en) Novel ω-phenylaminoalkanoic acids and their salts, in which a group derived from 19-norsteroid is substituted on the aromatic nucleus, their production method, novel intermediates of this production method, their use as drugs Uses and compositions containing them
US6740645B1 (en) 17β-acyl-17α-propynyl-11β-(cyclic amino) aryl steroids and their derivatives having antagonist hormonal properties
US5134136A (en) 14α,17α-ethanoestratrienes
US5124321A (en) 17-halomethylene estratrienes
JPH0515720B2 (en)
US7199115B2 (en) 17α-fluorosteroids, pharmaceutical compositions containing 17α-fluorosteroids and a method of making them
FI91158C (en) Process for Preparation of Therapeutically Active 6,21-Dimethyl-19-Norprogestone Derivatives
US8445469B2 (en) 18-methyl-19-nor-17-pregn-4-ene-21,17-carbolactones, as well as pharmaceutical preparations that contain the latter
US5439902A (en) 14α, 16α-ethanoand 14α, 16α-etheno-estratrienes
HU208152B (en) Process for producing 19-norprogesterone derivatives alkylated in 17/21-position and pharmaceutical compositions comprising such compounds
SK19492000A3 (en) Novel 17-halogenated 19-nor steroids, method and intermediates for preparing same, use as medicines and pharmaceutical compositions containing same
AU708135C (en) New 19-nor-pregnene derivatives

Legal Events

Date Code Title Description
AS Assignment

Owner name: SCHERING AKTIENGESELLSCHAFT, BERLIN AND BERGKAMEN,

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNORS:JUNGBLUT, PETER;WIECHERT, RUDOLF;BITTLER, DIETER;REEL/FRAME:005039/0684;SIGNING DATES FROM 19890131 TO 19890203

FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

CC Certificate of correction
FPAY Fee payment

Year of fee payment: 4

REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
FP Lapsed due to failure to pay maintenance fee

Effective date: 19981211

STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载